CytoDyn Merger Does More Than Expand Into Metastatic Cancer [Seeking Alpha]
CYTODYN INC (CYDY)
NASDAQ:AMEX Investor Relations:
ir.cytodyn.com
Company Research
Source: Seeking Alpha
Summary The Acquisition CytoDyn, Inc. ( OTCQB:CYDY ) is a transforming company. CytoDyn recently announced the definitive agreement to close the ProstaGene acquisition on August 28, 2018. This deal will allow ProstaGene to utilize CytoDyn’s PRO 140, a CCR5 inhibitor, for cancer clinical trials. On any number of metrics, this deal was done on a very forward-looking basis. In retrospect, this could have been one of the biggest bargains in cancer research consummated. This was a 100% equity deal that called for the exchange of 27 million shares, with an estimated market value of $14.85 million of ProstaGene, in exchange for research that has the potential to obstruct the metastasis of cancer in humans, making PRO 140 a platform technology. Metastasis significantly lowers a patient's prognosis and is a primary driver of death from cancer. This is very significant because metastatic cancer dramatically decreases patients’ prognoses. A treatment that can limit or prevent metas
Show less
Read more
Impact Snapshot
Event Time:
CYDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYDY alerts
High impacting CYTODYN INC news events
Weekly update
A roundup of the hottest topics
CYDY
News
- CytoDyn Announces FDA Has Lifted Clinical Hold [Yahoo! Finance]Yahoo! Finance
- CytoDyn Announces FDA Has Lifted Clinical HoldGlobeNewswire
- CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma [Yahoo! Finance]Yahoo! Finance
- CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in GlioblastomaGlobeNewswire
- CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO [Yahoo! Finance]Yahoo! Finance
CYDY
Sec Filings
- 4/16/24 - Form 424B3
- 4/16/24 - Form 424B3
- 4/15/24 - Form 10-Q
- CYDY's page on the SEC website